Table 3 Stratified analysis of the cDDD for bisphosphonate and non-bisphosphonate users.
From: Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
Case 1: bisphosphonate users | ||||
|---|---|---|---|---|
pSS | Bisphosphonate users cDDD < 224 | Bisphosphonate users cDDD ≥ 224 | ||
ADJ. HR | 95% CI | ADJ. HR | 95% CI | |
No (Ref.) | 1.000 | 1.000 | ||
Yes | 2.407* | (1.412–7.790) | 2.143* | (1.046–4.393) |
Case 2: Non-bisphosphonate users | ||||
|---|---|---|---|---|
pSS | Non-bisphosphonate users cDDD < 224 | Non-bisphosphonate users cDDD ≥ 224 | ||
ADJ. HR | 95% CI | ADJ. HR | 95% CI | |
No (ref.) | 1.000 | 1.000 | ||
Yes | 0.447 | (0.128–1.562) | 0.549 | (0.121–2.493) |
